Close Menu
    GCC TabloidGCC Tabloid
    • Automotive

      Jaguar Type 01 electric GT debuts with 1,030 PS

      October 7, 2026

      Japan new car sales rise 1.8% in first half of 2026

      July 2, 2026

      Porsche reveals bespoke 911 GT3 RS in Macadamiametallic

      May 18, 2026

      Mercedes-Benz unveils electric C-Class in Seoul

      April 21, 2026

      2027 Mercedes-Benz S-Class adds DIGITAL LIGHT micro-LEDs

      January 30, 2026
    • Business

      AfDB backs Morocco reforms and climate resilience with €434.4m

      November 14, 2026

      DP World partner ATI wins 25-year Manila port renewal

      November 13, 2026

      ADB flags $264 billion yearly ASEAN infrastructure gap

      November 12, 2026

      Amin Adam questions how Ghana will fund $10bn New Economy

      November 11, 2026

      Samsung Electronics cash assets hit record 214.8 trillion won

      November 9, 2026
    • Entertainment

      Sony confirms God of War trilogy remake and PS5 prequel

      February 13, 2026

      Apple Arcade adds Jeopardy and NFL games in September update

      August 19, 2025

      Moscow hosts historic 47th international festival

      April 19, 2025

      Legal action against ‘Ketamine Queen,’ doctors in Perry overdose

      August 17, 2024

      Web3 leader Immutable rolls out $50M gaming rewards initiative

      April 27, 2024
    • Health

      Yellow fever kills 18 across nine African nations, WHO says

      November 7, 2026

      Dengue kills 173 in October as Bangladesh toll climbs to 418

      November 2, 2026

      Ebola deaths in DR Congo reach 5,340, fatality rate at 51.6%

      November 2, 2026

      Ebola death toll in DR Congo nears 4,900 as cases pass 10,000

      October 28, 2026

      Malaria kills 22 in Namibia’s Zambezi Region as cases rise

      October 26, 2026
    • Lifestyle

      Adidas unveils Treadflow, a treadmill shoe innovation

      August 24, 2025

      U.S. Polo Assn.’s fall-winter 2024 line inspired by Salt Lake City

      September 20, 2024

      JP Morgan funds Fresha with $31 million for AI and robotics growth

      August 23, 2024

      Adidas, Highsnobiety debut limited-edition sneakers

      January 6, 2024

      Unraveling Starbucks’ phenomenon as a worldwide coffee powerhouse

      September 1, 2023
    • Luxury

      Global luxury market contracts for first time since Great Recession

      November 18, 2024

      Uncover the allure of Rolex Deepsea – luxury awaits.

      April 10, 2024

      Beyond timekeeping to the prestige of the Rolex Day-Date

      March 2, 2024

      Rare uncut emerald dazzles at Sharjah show

      February 1, 2024

      Porsche and Frauscher launch the electric 850 Fantom Air

      October 17, 2023
    • News

      Sheikh Mohamed receives Arab League chief Nabil Fahmy

      November 14, 2026

      Three nations launch carbon crediting initiative at COP31

      November 13, 2026

      Nigeria and EU seal readmission deal after decade of talks

      November 12, 2026

      Modi and Zelenskyy discuss peace efforts and bilateral ties

      November 11, 2026

      UAE and Tanzania explore wider economic and trade cooperation

      November 9, 2026
    • Sports

      Africa hosts first Olympic event as Dakar 2026 YOG begins

      October 30, 2026

      Messi ends Argentina career with 207 caps and 125 goals

      September 1, 2026

      FIA President meets with Hungarian PM and Czech President

      July 28, 2026

      Portugal fall to Spain as Ronaldo legacy closes

      July 7, 2026

      Brazil exits World Cup after Norway Round of 16 victory

      July 6, 2026
    • Technology

      MEAPMP Launches: Revamped Independent Ad-Tech & Premium Media Buying Across MEA

      November 3, 2026

      Sam Altman calls UAE most forward-looking country on AI

      November 3, 2026

      Apple iPhone Duo sets a new benchmark for foldable design

      November 2, 2026

      Apple brings Touch and PROLED XDR display to MacBook Pro

      October 29, 2026

      Integrated Identity Enters Global Top 0.1% with Rare 100/100 Google PageSpeed

      October 29, 2026
    • Travel

      Türkiye aims to rank sixth in global tourism revenue

      October 21, 2026

      Air Arabia launches Sharjah flights to Amman City Airport

      October 9, 2026

      Air Arabia resumes daily Ras Al Khaimah Kozhikode service

      October 7, 2026

      flydubai showcases growing Syria network with daily flights

      September 29, 2026

      Emirates enters winter season with strong booking momentum

      September 15, 2026
    GCC TabloidGCC Tabloid
    Home » SIRONA 3-Year Results: Sirolimus-Coated Balloon Shows Higher Freedom From Repeat Revascularization Than Paclitaxel-Coated Balloons in Femoropopliteal Disease
    PR Newswire

    SIRONA 3-Year Results: Sirolimus-Coated Balloon Shows Higher Freedom From Repeat Revascularization Than Paclitaxel-Coated Balloons in Femoropopliteal Disease

    November 3, 2026
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    Late-breaking data presented at TCT 2026 and published simultaneously in JACC: Cardiovascular Interventions show durable benefit with MagicTouch PTA, with similar walking capacity, quality of life and safety in both groups

    TAMPA, Fla., Nov. 3, 2026 /PRNewswire/ — Three-year results from the randomized SIRONA trial show that patients with femoropopliteal artery disease treated with the MagicTouch PTA (Concept Medical) sirolimus-coated balloon (SCB) were more often free from clinically driven target lesion revascularization (cdTLR) than those treated with paclitaxel-coated balloons (PCB). There were no between-group differences in walking capacity, quality of life or clinical safety.

    Three-year SIRONA results presented at TCT 2026 show higher freedom from repeat revascularisation with the MagicTouch PTA Sirolimus Coated Balloon versus paclitaxel-coated balloons in femoropopliteal disease

    Principal Investigator Prof. Ulf Teichgräber, Jena University Hospital, Germany, presented the results as a late-breaking clinical science presentation at TCT 2026, with simultaneous publication in JACC: Cardiovascular Interventions. It is the first randomized comparison of the two technologies to report beyond two years.

    SIRONA is an investigator-initiated, multicenter randomized trial at 25 centers in Germany and Austria. A total of 482 patients with symptomatic femoropopliteal disease (96.3% with intermittent claudication) were randomized 1:1 to SCB or PCB angioplasty after successful lesion predilation. It previously met its 12-month non-inferiority primary endpoints for patency and safety.

    At three years, freedom from cdTLR was 88.2% with SCB and 80.2% with PCB, an absolute difference of 8.0 points (95% CI 1.0–14.8; P=0.01; hazard ratio 0.60, 95% CI 0.36–0.97; log-rank P=0.03). Curves separated after year one.

    Patient-reported walking distance and quality of life improved in both groups and were sustained through three years, with no between-group differences. Safety outcomes were similar: all-cause mortality was 7.4% in both groups (HR 1.16, 95% CI 0.59–2.28), major amputation was rare (one vs two patients), and amputation-free survival was 92.1% with SCB and 92.2% with PCB. Freedom from clinically driven target vessel revascularization did not differ significantly (83.8% vs 79.1%; P=0.27).

    The findings come amid renewed scrutiny of paclitaxel-coated devices after the SWEDEPAD 2 trial, which led the 2026 European Society for Vascular Surgery guideline update to recommend a more cautious approach to their use in claudication.

    As SIRONA was powered for its 12-month endpoints, the investigators noted that three-year analyses are exploratory and the cdTLR finding requires confirmation. Follow-up will continue to five years.

    Prof. Ulf Teichgräber, Principal Investigator, said: “Patients in both groups did well; those treated with the sirolimus-coated balloon needed fewer repeat procedures at the target lesion, with the difference emerging after the first year. Five-year follow-up will tell us whether this benefit holds.”

    Dr. Manish Doshi, Founder and Managing Director, Concept Medical, added: “We thank the SIRONA investigators and patients. These results add to the randomized evidence for MagicTouch PTA which is more validation of product and technology and we remain committed to rigorous long-term data for sirolimus-coated balloons in peripheral artery disease”

    Source: SIRONA randomized controlled trial (NCT04475783), presented as a late-breaking clinical science presentation at TCT 2026 by Prof. Ulf Teichgräber on November 2, 2026, and simultaneously published in JACC: Cardiovascular Interventions (DOI: 10.1016/j.jcin.2026.10.020). The trial was funded by Concept Medical Inc., which had no role in data analysis, interpretation, or manuscript preparation.

    About MagicTouch PTA

    MagicTouch PTA, developed by Concept Medical Inc., uses proprietary Nanoluté technology to deliver sub-micron particles of sirolimus encapsulated in a biocompatible carrier, ensuring deep penetration into the vessel wall. The device has received CE Mark approval in Europe and Breakthrough Device Designation from the U.S. FDA for the treatment of below-the-knee disease, as well as IDE approvals for both SFA and BTK treatment with ongoing trials.

    About Concept Medical Inc.

    Concept Medical Inc., headquartered in Tampa, Florida, has a global presence and is dedicated to enhancing patient care through cutting-edge research and development of drug-delivery technologies. Its proprietary platforms are designed to deliver pharmaceutical agents across vascular luminal surfaces with unparalleled precision. Concept Medical is the developer of the MagicTouch family of sirolimus-coated balloons (SCB) — the world’s first and most utilized SCB technology — well recognized for its versatility and efficacy in treating coronary and peripheral artery disease. The MagicTouch and Abluminus product lines have been used to treat over a million patients globally.

    For more information, please visit www.conceptmedical.com. 

    CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device. Product availability is subject to regulatory approval in respective countries. MagicTouch PTA is an investigational device in the United States and is approved for use in clinical trials only.

     

    Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/sirona-3-year-results-sirolimus-coated-balloon-shows-higher-freedom-from-repeat-revascularization-than-paclitaxel-coated-balloons-in-femoropopliteal-disease-302927706.html

    Related Posts

    Thunes Expands Real-Time Payouts to Bhutan, Unlocking the Nation’s Remittance Market

    November 16, 2026

    WHO Bahrain and RCSI Medical University of Bahrain sign agreement to strengthen health workforce education, research and community engagement

    November 15, 2026

    Innovative Immunology Biotech Windward Bio Lists on Nasdaq

    November 14, 2026

    Alwaleed Philanthropies and The Research, Development and Innovation Authority Sign Strategic Partnership valued at SAR 10 million to Advance Innovation and Technology Solutions

    November 13, 2026

    GHA Honors The Second Affiliated Hospital Zhejiang University School of Medicine with Distinction for Excellence in International Medical Travel Patient Experience

    November 13, 2026

    81% of Software Teams Have Merged AI-Written Code They Didn’t Fully Understand, Finds TestMu AI’s State of AI in Quality Engineering 2026 Report

    November 13, 2026
    Latest News

    Sheikh Mohamed receives Arab League chief Nabil Fahmy

    November 14, 2026

    AfDB backs Morocco reforms and climate resilience with €434.4m

    November 14, 2026

    Three nations launch carbon crediting initiative at COP31

    November 13, 2026
    © 2026 GCC Tabloid | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.